Literature DB >> 24573997

Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Carolina L Haass-Koffler1, Lorenzo Leggio, George A Kenna.   

Abstract

Research on the concept of craving may lead to better understanding of the biobehavioural circuitries that contribute to the complexity of alcohol use disorders (AUDs). The experiences described as craving or desire to drink are often associated with physical responses such as increased salivation and heart rate, and alteration of stress hormones, as well as psychological responses such as anxiety and depression. Greater craving has been associated with an increased probability of alcohol relapse. Reversal of craving, which is understood as a symptom of protracted abstinence, offers the possibility of preventing relapses and treating alcoholism. Various medications have been studied to establish whether they are able to reduce craving; however, the results obtained from clinical studies have been inconsistent. Here, we review the interdisciplinary models developed to evaluate craving, then the different approaches used to assess and measure craving and, finally, the medications utilized and tested to lessen craving in patients suffering from AUDs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24573997      PMCID: PMC3990000          DOI: 10.1007/s40263-014-0149-3

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  247 in total

1.  Microdialysis of dopamine in the nucleus accumbens of alcohol-preferring (P) rats during anticipation and operant self-administration of ethanol.

Authors:  Roberto I Melendez; Zachary A Rodd-Henricks; Eric A Engleman; Ting-Kai Li; William J McBride; James M Murphy
Journal:  Alcohol Clin Exp Res       Date:  2002-03       Impact factor: 3.455

2.  Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients.

Authors:  G Addolorato; M Cibin; F Caputo; E Capristo; G L Gessa; G F Stefanini; G Gasbarrini
Journal:  Drug Alcohol Depend       Date:  1998-12-01       Impact factor: 4.492

3.  Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence.

Authors:  Raymond F Anton; Darlene H Moak; Patricia Latham; L Randolph Waid; Hugh Myrick; Konstantin Voronin; Angelica Thevos; Wei Wang; Robert Woolson
Journal:  J Clin Psychopharmacol       Date:  2005-08       Impact factor: 3.153

4.  Olanzapine increases weight and serum triglyceride levels.

Authors:  D N Osser; D M Najarian; R L Dufresne
Journal:  J Clin Psychiatry       Date:  1999-11       Impact factor: 4.384

Review 5.  Measurement of alcohol craving.

Authors:  David J Kavanagh; Dixie J Statham; Gerald F X Feeney; Ross McD Young; Jon May; Jackie Andrade; Jason P Connor
Journal:  Addict Behav       Date:  2012-09-09       Impact factor: 3.913

6.  Measuring alcohol craving: development of the Alcohol Craving Experience questionnaire.

Authors:  Dixie J Statham; Jason P Connor; David J Kavanagh; Gerald F X Feeney; Ross Mc D Young; Jon May; Jackie Andrade
Journal:  Addiction       Date:  2011-05-12       Impact factor: 6.526

7.  Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching.

Authors:  A J Jaffe; B Rounsaville; G Chang; R S Schottenfeld; R E Meyer; S S O'Malley
Journal:  J Consult Clin Psychol       Date:  1996-10

8.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Arch Gen Psychiatry       Date:  2007-09

9.  High variability in the exposure of baclofen in alcohol-dependent patients.

Authors:  Amélie Marsot; Bruce Imbert; Jean-Claude Alvarez; Stanislas Grassin-Delyle; Isabelle Jaquet; Christophe Lançon; Nicolas Simon
Journal:  Alcohol Clin Exp Res       Date:  2013-08-22       Impact factor: 3.455

Review 10.  Cognitive concepts of craving.

Authors:  S T Tiffany
Journal:  Alcohol Res Health       Date:  1999
View more
  33 in total

1.  A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.

Authors:  Carolina L Haass-Koffler; Kimberly Goodyear; Victoria M Long; Harrison H Tran; Antonella Loche; Roberto Cacciaglia; Robert M Swift; Lorenzo Leggio
Journal:  Eur J Pharm Sci       Date:  2017-08-01       Impact factor: 4.384

2.  Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; Dena Davidson; Robert M Swift
Journal:  Alcohol Clin Exp Res       Date:  2015-04       Impact factor: 3.455

3.  Chronic intermittent ethanol exposure selectively alters the expression of Gα subunit isoforms and RGS subtypes in rat prefrontal cortex.

Authors:  D J Luessen; H Sun; M M McGinnis; B A McCool; R Chen
Journal:  Brain Res       Date:  2017-07-21       Impact factor: 3.252

Review 4.  Multisensory Environments to Measure Craving During Functional Magnetic Resonance Imaging.

Authors:  Kimberly Goodyear
Journal:  Alcohol Alcohol       Date:  2019-05-01       Impact factor: 2.826

Review 5.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 6.  Current Evidence on Heart Rate Variability Biofeedback as a Complementary Anticraving Intervention.

Authors:  Nour Alayan; Lucille Eller; Marsha E Bates; Dennis P Carmody
Journal:  J Altern Complement Med       Date:  2018-05-21       Impact factor: 2.579

Review 7.  Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation.

Authors:  T J Phillips; C Reed; R Pastor
Journal:  Genes Brain Behav       Date:  2015-01       Impact factor: 3.449

Review 8.  Pharmacotherapy for alcoholic patients with alcoholic liver disease.

Authors:  Cynthia L Vuittonet; Michael Halse; Lorenzo Leggio; Samuel B Fricchione; Michael Brickley; Carolina L Haass-Koffler; Tonya Tavares; Robert M Swift; George A Kenna
Journal:  Am J Health Syst Pharm       Date:  2014-08-01       Impact factor: 2.637

9.  Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans.

Authors:  Carolina L Haass-Koffler; Kimberly Goodyear; Antonella Loche; Victoria M Long; Carla Lobina; Harrison H Tran; Roberto Cacciaglia; Robert M Swift; Giancarlo Colombo; Lorenzo Leggio
Journal:  J Psychopharmacol       Date:  2018-01-23       Impact factor: 4.153

10.  A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder.

Authors:  E Sherwood Brown; Erin Van Enkevort; Alexandra Kulikova; Chastity Escalante; Alyson Nakamura; Elena I Ivleva; Traci Holmes
Journal:  Alcohol Clin Exp Res       Date:  2018-12-24       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.